-
Gilead Sciences Inc. (NASDAQ:GILD) gained $5.38 (11%) to $54.69 on Friday after releasing preliminary rapid virologic response data from the Phase IIb ELECTRON trial of HCV product GS-7977 in its financial results …
Published on 2/3/2012
-
MannKind Corp. (NASDAQ:MNKD) raised $75 million through the sale of 31.3 million units at $2.40 in a bumped-up follow-on underwritten by Jefferies; Piper Jaffray; Cowen; and JMP Securities. Each unit comprises a share …
Published on 2/3/2012
-
Research tool and services supplier Transgenomic Inc. (OTCBB:TBIO) raised $19 million through a private placement of 19 million shares at $1. The price is a 16% discount to Transgenomic's close of $1.19 on Thursday, …
Published on 2/3/2012
-
Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q11 non-GAAP diluted EPS of $0.97, missing by $0.08 the Street's estimate of $1.05 but up from $0.95 in 4Q10. Revenues for the quarter were $2.2 billion, above the Street's …
Published on 2/2/2012
-
Insero Health Inc. (Miami, Fla.) raised $1.1 million in a seed round from the Reich Group. Insero is developing huperzine for epilepsy and related diseases. The NMDA receptor antagonist and acetylcholinesterase (AChE) …
Published on 2/2/2012
-
Merrimack Pharmaceuticals Inc. (Cambridge, Mass) has postponed its IPO, according to a banker familiar with the deal who did not want to be named. The company had planned to sell 16.7 million shares at $8-$10. A $9 …
Published on 2/2/2012
-
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported 4Q11 and 2011 financial results that beat the Street's estimates as revenue from newly launched HCV drug Incivek telaprevir reached nearly $1 billion in 2011. Vertex …
Published on 2/2/2012
-
Ardea Biosciences Inc. (NASDAQ:RDEA) raised $144.5 million through the sale of 8.5 million shares at $17 in a follow-on underwritten by Jefferies; Cowen; Lazard; Leerink Swann; Oppenheimer; Wells Fargo; JMP Securities; …
Published on 2/1/2012
-
Medivation Inc. (NASDAQ:MDVN) jumped $12.16 (22%) to $67.57 on Wednesday after reporting additional data from the Phase III AFFIRM trial of MDV3100 to treat castration-resistant prostate cancer (CRPC) in patients …
Published on 2/1/2012
-
Roche (SIX:ROG; OTCQX:RHHBY) said it expects sales of ophthalmic drug Lucentis ranibizumab in the U.S. to decline in 2012 compared to 2011 as a result of competition from newly launched Eylea aflibercept from Regeneron …
Published on 2/1/2012
-
Targovax A/S (Lysaker, Norway) raised NOK13 million ($2.2 million) in a series A round led by existing investor Radium Hospital Research Foundation. New investors Birk Venture and RO Invest participated, along with …
Published on 2/1/2012
-
Biogen Idec Inc. (NASDAQ:BIIB) reported 4Q11 non-GAAP diluted EPS of $1.51, beating by $0.02 the Street's estimate of $1.49 and up 6% from $1.42 in 4Q10. Fourth quarter revenues were $1.33 billion, slightly above the …
Published on 1/31/2012
-
DBV Technologies (Bagneux, France) is planning an IPO on Euronext Paris. DBV is developing allergy treatments using its Viaskin technology to deliver proteins epicutaneously. DBV's Viaskin Peanut is in Phase II testing …
Published on 1/31/2012
-
MannKind Corp. (NASDAQ:MNKD) proposed to raise $50 million through the sale of units in a follow-on and up to $161 million through the sale of senior secured convertible notes. The follow-on is underwritten by Jefferies…
Published on 1/31/2012
-
Autoimmune and allergy company Regimmune Corp. (Tokyo, Japan) raised $5 million in the first tranche of a preferred series A round co-led by Daiwa Enterprise Co. Ltd. and Japan Asia Investment Corp. (JAIC). Other …
Published on 1/31/2012
-
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $2.12 (17%) to $14.26 on Monday after FDA approved once-weekly Bydureon exenatide on Friday to treat Type II diabetes. Amylin said the drug will be available in February …
Published on 1/30/2012
-
GTx Inc. (NASDAQ:GTXI) jumped $1.94 (49%) to $5.88 on Monday after Citi analyst Lucy Lu raised her price target on the stock to $19 from $8. Lu said the new target accounts for the addition of GTx's Ostarine (GTx-024) …
Published on 1/30/2012
-
The Experiment Fund, a new seed-stage investment fund intended to support student startups in the Cambridge, Mass., area, debuted with backing from New Enterprise Associates. The fund expects to provide each startup …
Published on 1/30/2012
-
Molecular diagnostics company Xagenic Inc. (Toronto, Ontario) raised C$10 million ($10 million) in a series A round from new investors co-led by CTI Life Sciences Fund and the Ontario Emerging Technologies Fund. Qiagen …
Published on 1/30/2012
-
Adocia S.A.S. (Lyon, France) unveiled details of its planned IPO on Euronext Paris and private placement outside the U.S. The company hopes to sell 1.4 million shares at EUR 13-EUR 15.88. If sold in full at the midpoint…
Published on 1/27/2012
-
Amgen Inc. (NASDAQ:AMGN) reported 4Q11 diluted non-GAAP EPS of $1.21, missing by a penny the Street's estimate of $1.22, but up $0.04 from $1.17 in 4Q10. Revenue for the quarter rose 4% to $4 billion, coming in slightly…
Published on 1/26/2012
-
Trius Therapeutics Inc. (NASDAQ:TSRX) raised $45.2 million through the sale of 8.6 million shares at $5.25 in a follow-on underwritten by Citi; Piper Jaffray; Canaccord; and Ladenburg Thalmann. Trius proposed the …
Published on 1/26/2012
-
Complete Genomics Inc. (NASDAQ:GNOM) and Pacific Biosciences of California Inc. (NASDAQ:PACB) gained on Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) made an unsolicited offer to acquire sequencing and microarray company…
Published on 1/25/2012
-
Novartis AG (NYSE:NVS; SIX:NOVN) reported 4Q11 financial results below the Street's estimates on Wednesday. Core EPS for the quarter was $1.23, missing by a penny the Street's estimate of $1.24, but up 13% from $1.14 in…
Published on 1/25/2012
-
Prosensa B.V. (Leiden, the Netherlands) raised EUR 23 million ($29.7 million) in a financing led by new investor New Enterprise Associates. Existing investors Abingworth; Life Sciences Partners; Gimv; Idinvest Partners;…
Published on 1/25/2012